Bro1 proteins determine tumor immune evasion and metastasis by controlling secretion or degradation of multivesicular bodies
Developmental Cell · 2025-08 · 60 (15) · 2114-2130.e9
DOI: 10.1016/j.devcel.2025.03.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Developmental Cell, 2025-08. Verfasst von Nai Yang Yeat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan; Chemical Biology and Molecular Biophysics Program, Taiwan International Gradu…. Hauptthemen laut MEDLINE: Tumor Escape, Neoplasm Metastasis, Multivesicular Bodies, GTP-Binding Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Academia Sinica, National Science and Technology Council, Institute of Biomedical Science.
Abstract (Originalsprache)
Exosomes play pleiotropic tumor-promoting functions and are secreted by fusion of multivesicular bodies (MVBs) with the plasma membrane. However, MVBs are also directed to lysosomes for degradation, and the mechanism controlling different fates of MVBs remains elusive. Here, we show that the pro-tumor protein WDR4 enhances exosome secretion from mouse and human cancer cells through degrading the endosomal sorting complex required for transport (ESCRT)-associated Bro1-family protein PTPN23. Mechanistically, PTPN23 and ALIX compete for binding to syntenin, thereby directing MVBs toward degradation and secretion, respectively. ALIX, but not PTPN23, recruits actin-capping proteins CAPZA1/CAPZB to prevent branched filamentous actin (F-actin) accumulation around MVBs, thus enabling MVBs trafficking to the cell periphery for secretion. Functionally, WDR4/ALIX-dependent exosomes load a set of pro-tumor proteins through LAMP2A, thereby potentiating metastasis and immune evasion in mice. Our study highlights a previously unappreciated coupling between the biogenesis mechanism and the fate decision of MVBs and its importance in determining exosomal cargos, which have a profound impact on tumor progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan; Chemical Biology and Molecular Biophysics Program, Taiwan International Graduate Program, Academia Sinica, Taipei 115, Taiwan; Department of Chemis…
- Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan; Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
- Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan; Institute of Biochemical Sciences, College of Life Science, National Taiwan University, Taipei 106, Taiwan.
- Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei 115, Taiwan.
- Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan; Chemical Biology and Molecular Biophysics Program, Taiwan International Graduate Program, Academia Sinica, Taipei 115, Taiwan; Institute of Molecul…
Förderung
- Academia Sinica
- National Science and Technology Council
- Institute of Biomedical Science
Zitieren
APA
Yeat, N. Y., Liu, L. H., Chang, Y. H., Lai, C. P., & Chen, R. H. (2025). Bro1 proteins determine tumor immune evasion and metastasis by controlling secretion or degradation of multivesicular bodies. Developmental Cell, 60(15), 2114-2130.e9. https://doi.org/10.1016/j.devcel.2025.03.008
Vancouver
Yeat NY, Liu LH, Chang YH, Lai CP, Chen RH. Bro1 proteins determine tumor immune evasion and metastasis by controlling secretion or degradation of multivesicular bodies. Developmental Cell. 2025;60(15):2114-2130.e9. doi:10.1016/j.devcel.2025.03.008
BibTeX
@article{Yeat2025,
author = {Yeat, Nai Yang and Liu, Li-Heng and Chang, Yu-Hsuan and Lai, Charles Pin-Kuang and Chen, Ruey-Hwa},
title = {Bro1 proteins determine tumor immune evasion and metastasis by controlling secretion or degradation of multivesicular bodies},
journal = {Developmental Cell},
year = {2025},
volume = {60},
number = {15},
pages = {2114--2130.e9},
doi = {10.1016/j.devcel.2025.03.008}
}
EUVIMED